Skip to main content
Clinical Trials/NCT02531347
NCT02531347CompletedNot Applicable

Treatment of Hypertension Using Telemedical Home Blood Pressure Measurements

Erling Bjerregaard Pedersen0 sites375 target enrollmentStarted: March 1, 2011Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
375
Primary Endpoint
Blood pressure reduction

Study Overview

Brief Summary

The purpose of the study is to compare antihypertensive treatment based on either conventional blood pressure measurements or telemedical home blood pressure measurements.

Hypothesis is that telemedical treatment of hypertension is more effective in lowering blood pressure, is more cost-effective and provides better quality of life.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
55 Years to 64 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Age 55 to 64 years
  • Registered address in the Municipality of Holstebro
  • Enrolment at a practice of one of the general practitioners who had agreed to participate in the study
  • Telemedical home blood pressure measurement with ≥12 measurements on day 2 and
  • Elevated home blood pressure ≥135/85 (if diagnosed diabetes, chronic kidney disease or prior stroke ≥130/80)
  • Hypertension confirmed by daytime ambulatory blood pressure ≥135/85 (if diagnosed diabetes, chronic kidney disease or prior stroke ≥130/80)
  • ECG verified sinus rhythm

Exclusion Criteria

  • Unwillingness to participate
  • Normotension
  • Withdrawal of consent to participate

Outcomes

Primary Outcomes

Blood pressure reduction

Time Frame: 3 month

Difference in daytime ambulatory blood pressure from baseline to followup between intervention and control group

Secondary Outcomes

  • Number of patients reaching target blood pressure(3 month)

Investigators

Sponsor
Erling Bjerregaard Pedersen
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Erling Bjerregaard Pedersen

Professor, Chief Physician

Regional Hospital Holstebro

Similar Trials